Citadel Advisors
ANIX icon

Citadel Advisors’s Anixa Biosciences ANIX Stock Holding History

Citadel Advisors’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.3K Buy
+31,887
New +$88.7K ﹤0.01% 12776
2026
Q1 		– Sell
-29,692
Closed -$87.9K – 12917
2025
Q4 		$92.6K Sell
29,692
-66,318
-69% -$272K ﹤0.01% 11700
2025
Q3 		$317K Buy
96,010
+25,072
+35% +$79.3K ﹤0.01% 10230
2025
Q2 		$234K Buy
+70,938
New +$203K ﹤0.01% 10358
2025
Q1 		– Sell
-87,919
Closed -$251K – 14410
2024
Q4 		$204K Buy
87,919
+82,234
+1,447% +$255K ﹤0.01% 10423
2024
Q3 		$17.9K Buy
+5,685
New +$17.5K ﹤0.01% 12864
2024
Q2 		– Sell
-38,254
Closed -$119K – 14176
2024
Q1 		$119K Buy
38,254
+21,559
+129% +$86K ﹤0.01% 11111
2023
Q4 		$64.8K Sell
16,695
-23,880
-59% -$80.5K ﹤0.01% 11492
2023
Q3 		$133K Sell
40,575
-2,117
-5% -$7.41K ﹤0.01% 10531
2023
Q2 		$137K Buy
42,692
+31,478
+281% +$121K ﹤0.01% 10463
2023
Q1 		$48.2K Sell
11,214
-36,292
-76% -$159K ﹤0.01% 12199
2022
Q4 		$202K Buy
47,506
+27,896
+142% +$134K ﹤0.01% 10119
2022
Q3 		$97K Sell
19,610
-4,684
-19% -$19K ﹤0.01% 11118
2022
Q2 		$74K Buy
+24,294
New +$76.6K ﹤0.01% 11655
2022
Q1 		– Sell
-33,935
Closed -$101K – 13501
2021
Q4 		$101K Buy
33,935
+19,677
+138% +$79.6K ﹤0.01% 12714
2021
Q3 		$68K Buy
+14,258
New +$64.3K ﹤0.01% 13174
2021
Q2 		– Sell
-19,682
Closed -$83.8K – 13607
2021
Q1 		$92K Buy
19,682
+5,184
+36% +$24.8K ﹤0.01% 12535
2020
Q4 		$45K Buy
+14,498
New +$36.4K ﹤0.01% 10598

Other funds holding ANIX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Citadel Advisors's ANIX Position: Q2 2026 in Review

Citadel Advisors opened a new position in Anixa Biosciences (ANIX) in Q2 2026: 31,887 shares worth $89.3K. The stake represents ﹤0.01% of the portfolio and ranks #12776 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ANIX as recently as Q4 2025.

Citadel Advisors first reported a position in ANIX in Q4 2020 and has held it in 18 quarters since. The position peaked at $317K in Q3 2025. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

  • Citadel Advisors held 31,887 shares of Anixa Biosciences worth $89.3K as of Q2 2026.
  • Anixa Biosciences was a new Citadel Advisors position in Q2 2026.
  • Anixa Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12776 holding.
  • Citadel Advisors first reported a position in Anixa Biosciences in Q4 2020 and has held it in 18 quarters since.
  • Citadel Advisors's Anixa Biosciences position peaked at $317K in Q3 2025.
  • 62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.